Atorvastatin (atorvastatin) coated tablets 10 mg. №90

Atorvastatin (atorvastatin) Pfizer coated tablets 10 mg. №30

$65.00

Manufacturer: Germany

Atorvastatin Pfizer is used for the prevention of cardiovascular disease, as well as an adjunct to diet to reduce elevated levels of total cholesterol.

Category:

Description

Ingredients

active ingredient: atorvastatin;

1 tablet contains atorvastatin calcium, which is equivalent to 10 mg of atorvastatin;

other components: calcium carbonate; cellulose microcrystalline; lactose, monohydrate; croscarmellose sodium; polysorbate 80; hydroxypropyl cellulose; magnesium stearate; film coating material (hydroxypropyl methylcellulose, macrogol 8000, titanium dioxide (E 171), talc); simethicone emulsion (simethicone, emulsifying stearate, thickener, benzoic acid, sorbic acid).

Dosage form

Film-coated tablets.

Basic physical and chemical properties: white, round, film-coated tablets.

Pharmacotherapeutic group

The drugs lower the level of cholesterol and triglycerides in the blood serum. HMG-CoA reductase inhibitors. ATC code C10A A05.

Pharmacodynamics

Atorvastatin Pfizer is a synthetic lipid-lowering drug. Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early step in cholesterol biosynthesis that limits the rate of its formation.

Atorvastatin Pfizer is a selective competitive inhibitor of HMG-CoA reductase, an enzyme that determines the rate of conversion of 3-hydroxy-3-methylglutaryl coenzyme to mevalonate, a precursor of sterols, including cholesterol.

In animal models, Atorvastatin reduces plasma cholesterol and lipoprotein levels by inhibiting hepatic HMG-CoA reductase and cholesterol synthesis and by increasing the number of hepatic LDL receptors on cell surfaces to enhance Lp uptake and catabolism; Atorvastatin Pfizer also reduces LDL production in so many of these particles.

Atorvastatin Pfizer, like some of its metabolites, is pharmacologically active in humans. The main site of action of atorvastatin is the liver, which plays a major role in cholesterol synthesis and LDL clearance. The dose of the drug, in contrast to the systemic concentration of the drug, correlates better with a decrease in the level of LDL cholesterol. Individual selection of the dose of the drug should be carried out depending on the therapeutic response.

Indications

Prevention of cardiovascular disease in adults

For adult patients without symptomatic coronary artery disease but with multiple risk factors for coronary artery disease such as age, smoking, hypertension, low HDL, or a family history of early coronary artery disease, Atorvastatin Pfizer is indicated

  • reducing the risk of myocardial infarction;
  • reducing the risk of stroke;
  • reducing the risk of revascularization procedures and angina pectoris

For adult patients with type II diabetes mellitus and without symptomatic coronary artery disease, but with several risk factors for coronary artery disease, such as retinopathy, albuminuria, smoking, or arterial hypertension, Atorvastatin Pfizer is indicated for:

  • reducing the risk of myocardial infarction;
  • reducing the risk of stroke.

For adult patients with clinically significant ischemic heart disease, Atorvastatin Pfizer is indicated for:

  • reducing the risk of non-lethal myocardial infarction;
  • reducing the risk of fatal and non-fatal stroke;
  • reducing the risk of revascularization procedures;
  • reduced risk of hospitalization due to congestive heart failure;
  • reducing the risk of angina pectoris.

Hyperlipidemia

In adult patients

  • As an adjunct to diet to reduce elevated levels of total cholesterol, LDL cholesterol, apolipoprotein B and triglycerides, and to increase HDL cholesterol in patients with primary hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipid.
  • As an adjunct to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson type IV).
  • For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III), in cases where dieting is not effective enough.
  • To reduce total and LDL cholesterol in patients with homozygous familial hypercholesterolemia in addition to other lipid-lowering treatments (eg LDL apheresis) or when such treatments are not available.

In children

As an adjunct to a diet to reduce total cholesterol, LDL cholesterol, and apolipoprotein B in children 10 to 17 years of age with heterozygous familial hypercholesterolemia, if, after appropriate dietary therapy, the test results are:

  1. LDL cholesterol remains ³ 190 mg/dL (4.91 mmol/L) or
  2. LDL cholesterol ³ 160 mg/dL (4.14 mmol/L) and:
  • family history of early cardiovascular disease or
  • two or more other risk factors for cardiovascular disease are present in a pediatric patient.

Contraindications

  • Active liver disease, which may include persistent elevations in liver transaminases of unknown etiology;
  • hypersensitivity to any of the components of this drug;
  • pregnancy;
  • lactation.

Dosage and administration

Hyperlipidemia and mixed dyslipidemia

The recommended starting dose of Atorvastatin is 10 or 20 mg once daily. For patients requiring a significant reduction in LDL cholesterol (greater than 45%), therapy may be initiated at a dosage of 40 mg once daily. The dosage of the drug AtorvastatinPfizer is in the range from 10 to 80 mg 1 time per day. The drug can be taken as a single dose at any time and regardless of the meal. The initial and maintenance dose of Atorvastatin Pfizer should be selected individually depending on the goal of treatment and response. After initiation of treatment and/or after dose titration of Atorvastatin Pfizer, lipid levels should be analyzed within 2 to 4 weeks and the dose adjusted accordingly.

Heterozygous familial hypercholesterolemia in pediatric patients (ages 10 to 17 years)

The recommended starting dose of Atorvastatin is 10 mg/day; the usual dose range is 10 to 20 mg orally once a day. Doses of the drug should be selected individually in accordance with the recommended goal of treatment. Dose adjustments should be made at intervals of 4 weeks or more.

Homozygous familial hypercholesterolemia

The dose of Atorvastatin Pfizer for patients with homozygous familial hypercholesterolemia is 10 to 80 mg/day. AtorvastatinPfizer should be used as an adjunct to other lipid-lowering therapies (eg, LDL apheresis) or when lipid-lowering therapies are not available.

Simultaneous lipid-lowering therapy

Atorvastatin Pfizer can be used with bile acid sequestrants. The combination of HMG-CoA reductase inhibitors (statins) and fibrates should be used with caution.

Dosage for patients with impaired renal function

Kidney disease does not affect either plasma concentrations or LDL-C lowering with Atorvastatin Pfizer; therefore, dose adjustment of the drug for patients with impaired renal function is not required.

Dosage for patients taking ciclosporin, clarithromycin, itraconazole, or certain protease inhibitors

Treatment with Atorvastatin Pfizer should be avoided in patients taking ciclosporin or HIV protease inhibitors (tipranavir + ritonavir) or an inhibitor of hepatitis C virus protease (telaprevir). AtorvastatinPfizer should be used with caution in HIV patients taking lopinavir + ritonavir and should be used at the lowest dose. In patients taking clarithromycin, itraconazole, or in patients with HIV taking saquinavir + ritonavir, darunavir + ritonavir, fosamprenavir, or fosamprenavir + ritonavir in combination, the therapeutic dose of Atorvastatin Pfizer should be dose limited. the lowest required dose of Atorvastatin-Pfizer. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, treatment with Atorvastatin Pfizer should be limited to 40 mg. and it is also recommended to conduct appropriate clinical examinations to ensure the lowest required dose of the drug Atorvastatin.

Related products